Collaboration and License Agreement - Additional Information (Details) - USD ($)	1 Months Ended				3 Months Ended			9 Months Ended
	Oct. 31, 2022	Jul. 31, 2022	Jun. 30, 2020	May 30, 2020	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	May 31, 2020
Bristol-Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received					$ 50,000,000			$ 50,000,000
Bristol-Myers Squibb Company | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration term expiration period				42 months
Initial nonrefundable upfront fee received			$ 50,000,000.0
Non-refundable payment received										$ 50,000,000.0
Deferred revenue recognized					200,000		$ 300,000	1,300,000	$ 700,000
Revenue Recognized					0	$ 6,500,000	$ 0	0	$ 0
Deferred revenue					41,200,000	42,500,000		41,200,000
Deferred revenue, current					9,100,000	2,900,000		9,100,000
Deferred revenue, noncurrent					32,100,000	39,600,000		32,100,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received										301,000,000.0
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received										176,000,000.0
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received										$ 125,000,000.0
Roche
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received					134,626,000			134,626,000
Roche | Combined licenses
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received					105,327,000			105,327,000
Roche | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated period of completion of trials to get revenue		24 months
Initial nonrefundable upfront fee received								125,000,000.0
Non-refundable payment received					134,600,000			134,600,000
Collaboration revenue payment receivable	$ 4,000,000.0
Deferred revenue recognized					112,300,000			112,300,000
Deferred revenue					22,300,000	0		22,300,000
Deferred revenue, current					16,700,000	0		16,700,000
Deferred revenue, noncurrent					5,600,000	$ 0		5,600,000
Roche | Collaboration and License Agreement | Research and development services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized					4,300,000			4,300,000
Roche | Collaboration and License Agreement | Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones payments								1,172,000,000
Roche | Collaboration and License Agreement | Combined licenses
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized					105,300,000			105,300,000
Roche | Collaboration and License Agreement | Clinical trial materials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue receivable					5,600,000			5,600,000
Deferred revenue recognized					2,700,000			2,700,000
Roche | Collaboration and License Agreement | Additional clinical development plan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue receivable					$ 4,000,000.0			$ 4,000,000.0